Discrepancies in Medicaid Managed Care and Substance Use Disorder Treatment

Access to treatment for substance use disorders, particularly concerning alcohol and opioid-related conditions, can significantly enhance health outcomes for those covered by Medicaid insurance. Nearly 80% of state Medicaid programs require managed care plans to provide coverage for medications associated with alcohol use disorder (AUD) and opioid use disorder (OUD).

Research from the School of Public Health has identified substantial inconsistencies between state Medicaid mandates for substance use disorder (SUD) treatments and the policies implemented by Medicaid managed care plans. The study, published in The Milbank Quarterly, highlights that these discrepancies are more prevalent in Republican-majority states compared to Democratic-majority states.

Furthermore, the research revealed that many managed care plans require prior authorizations for SUD medications, despite state prohibitions against such requirements. These stipulations can create delays and obstacles in accessing essential treatments, impacting patient outcomes negatively.

Impact of Political Climate on Medicaid Policies

"About 80% of Medicaid enrollees in the U.S. receive their benefits through managed care plans," stated study lead author Sage Feltus. "States may direct these plans to cover treatments for alcohol and opioid use disorders without limitations like prior authorizations, but misalignment with state directives can hinder patients' timely access to essential medications."

Maureen Stewart, a research associate professor of health law, policy, and management, emphasized the importance of proper implementation and oversight for effective policy enforcement. The disconnect between intended policy and actual implementation remains a pressing issue within substance use treatment policies.

Substance Use Disorder Treatment Access and Compliance

In 2023, over 48 million individuals in the U.S. experienced a substance use disorder, with more than 100,000 deaths from drug overdoses. Effective treatments for OUD include medications like methadone and buprenorphine, while AUD treatments feature oral naltrexone and disulfiram. This study emphasizes the need to improve access to these vital treatments.

The study represents the first comprehensive analysis of Medicaid managed care policy alignment with state-mandated SUD treatment requirements. By linking survey data from state Medicaid officials with coverage data from 167 Medicaid managed care plans in 2021, researchers analyzed political impacts on policy compliance.

Study Insights and Recommendations

Data revealed that Democratic-leaning states more rigorously enforce medication coverage for AUD and OUD, though exceptions like methadone remain. Despite better overall alignment for AUD medications, compliance with prior authorization bans was significantly lower. Approximately 93% of plans covered the AUD medication oral naltrexone, but only 57% adhered to authorization bans.

Stewart suggests that state programs might benefit from clear contractual language mandating compliance, along with accountability measures and regular audits. Managed care plans are urged to ensure policy alignment with state regulations, especially concerning SUD treatment coverage and prior authorizations, to empower enrollees in making informed healthcare decisions.